Share ownership Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 06/02/2026 GMT			5-day change	1st Jan Change
61.99 ^USD	+4.15%		+12.61%	+14.92%

02-06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT
02-06	Citigroup Adjusts Bristol-Myers Squibb PT to $64 From $60, Maintains Neutral Rating	MT

Share class: Bristol-Myers Squibb Company

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,923,312,023	1,985,940,000 ( 67.93 %)	894,000,000 ( 30.58 %)	67.93 %

Major shareholders: Bristol-Myers Squibb Company

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.762 %	198,727,768	9.762 %	10 719 M $
BlackRock Advisors LLC 6.095 %	124,082,755	6.095 %	6 693 M $
STATE STREET CORPORATION 4.745 %	96,595,232	4.745 %	5 210 M $
JPMorgan Investment Management, Inc. 4.236 %	86,238,478	4.236 %	4 652 M $
Geode Capital Management LLC 2.287 %	46,554,300	2.287 %	2 511 M $
BlackRock Life Ltd. 2.183 %	44,434,847	2.183 %	2 397 M $
Norges Bank (13F) 1.649 %	33,574,290	1.649 %	1 811 M $
Ameriprise Financial Services LLC 1.595 %	32,473,834	1.595 %	1 752 M $
Capital Research & Management Co. (International Investors) 1.591 %	32,387,024	1.591 %	1 747 M $
Eaton Vance Management 1.369 %	27,867,869	1.369 %	1 503 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
VSM Wealth Advisory LLC 0.6974 %	20	0.6974 %	18 368 $

Name	Equities	%	Valuation
State Street Global Advisors Europe Ltd. 0.0183 %	372,956	0.0183 %	20 M $

Name	Equities	%	Valuation
Transcend Capital Advisors LLC -	109,175	-	7 861 $
Davenport & Co. LLC -	83,970	-	6 046 $
Maven Investment Partners US Ltd. (US) -	67,856	-	4 886 $
Purkiss Capital Advisors LLC -	26,450	-	1 904 $
FIFTH THIRD BANCORP -	20,000	-	1 440 $
Watts Gwilliam & Co. LLC -	20,000	-	1 440 $
Private Advisor Group LLC -	15,000	-	1 080 $
Two Sigma Securities LLC -	12,741	-	917 $
Rothschild Investment LLC -	166	-	12 $
OAKWORTH CAPITAL INC. -	125	-	9 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	61.72%
Other	8.92%
State Street Corp.	4.74%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.26%
Skandinaviska Enskilda Banken AB	0.18%
Swedbank AB	0.15%
Governments	0.14%
SEI Investments Co.	0.08%
Manulife Financial Corp.	0.07%
Danske Bank A/S	0.06%
ING Groep NV	0.05%
Individuals	0.04%
The Bank of Nova Scotia	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.03%
Old Republic International Corp.	0.03%
Fifth Third Bancorp	0.03%
Zurich Insurance Group AG	0.02%
Peapack-Gladstone Financial Corp.	0.02%
Hancock Whitney Corp.	0.02%
Kinsale Capital Group, Inc.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Regions Financial Corp.	0.01%
First Horizon Corp. (Tennessee)	0.01%
Phoenix Financial Ltd.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Banque Cantonale Vaudoise	0.01%
Unknown	23.04%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	56.33%
United Kingdom	9.39%
Canada	2.02%
Norway	1.92%
France	1.21%
Australia	1.14%
Sweden	0.7%
Japan	0.7%
Switzerland	0.67%
Netherlands	0.58%
Germany	0.43%
South Korea	0.32%
Belgium	0.2%
Ireland	0.2%
Denmark	0.18%
Luxembourg	0.15%
New Zealand	0.13%
Hong Kong	0.13%
Italy	0.1%
Spain	0.09%
Finland	0.07%
Austria	0.06%
Taiwan	0.05%
Individuals	0.04%
Singapore	0.04%
Czech Republic	0.03%
India	0.01%
United Arab Emirates	0.01%
Cayman Islands	0.01%
Israel	0.01%
Mexico	0.01%
China	0.01%
South Africa	0.01%
Liechtenstein	0.01%

Based on 1000 largest holdings

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 7.1% of net sales.

Employees

34,100

Sector

Pharmaceuticals

Calendar

04-30 - Q1 2026 Earnings Release

More about the company